<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03990298</url>
  </required_header>
  <id_info>
    <org_study_id>828956</org_study_id>
    <nct_id>NCT03990298</nct_id>
  </id_info>
  <brief_title>Prospective Use of Awake Endoscopy for Inspire Activation</brief_title>
  <official_title>Prospective Use of Awake Endoscopy to Direct Inspire Therapy for Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to examine a new method of device configuration for the Inspire
      upper airway stimulator. First, the investigators will attempt to determine optimal
      configuration by quantifying changes in upper airway size with different implant
      configurations using awake nasal endoscopy. The configuration/voltage that results in the
      greatest increase in upper airway size and is tolerated by the patient will be selected.
      Participants will then undergo a sleep study so that increased airway size may be correlated
      with changes in sleep study parameters including AHI and oxygen desaturation index (ODI).
      Airway size and sleep study parameters using the standard device configuration (+-+)/voltage
      will be compared to airway size and sleep study parameters using the test, or &quot;optimal,&quot;
      configuration/voltage to determine the usefulness of awake endoscopy in activation of the
      Inspire device.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">June 9, 2020</completion_date>
  <primary_completion_date type="Actual">June 9, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in AHI</measure>
    <time_frame>Visit 2 - Titration Polysomnogram 8-10 weeks post-implant</time_frame>
    <description>Change in Apnea-Hypopnea Index with test configuration compared to standard configuration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ODI</measure>
    <time_frame>Visit 2 - Titration Polysomnogram 8-10 weeks post-implant</time_frame>
    <description>Change in oxygen desaturation index with test configuration compared to standard configuration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in airway size</measure>
    <time_frame>Visit 1 - Awake Endoscopy 4 weeks post-implant</time_frame>
    <description>Percent changes in cross-sectional airway size at the level of the retropalatal and retroglossal regions using different device configuration settings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of change in airway size to change in AHI/ODI</measure>
    <time_frame>Visit 1 (4 weeks post-implant) and Visit 2 (8-10 weeks post-implant)</time_frame>
    <description>The degree to which changes in airway size correlate with changes in sleep study parameters including AHI and ODI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Awake endoscopic exam will be performed to measure airway size in the retropalatal and retroglossal upper airway regions using different Inspire implant configurations and voltages.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Awake endoscopy</intervention_name>
    <description>Awake endoscopic exam will be performed to measure airway size in the retropalatal and retroglossal upper airway regions using different Inspire implant configurations and voltages. The optimal test configuration determined on endoscopy will be tested during a sleep study and compared to the standard-of-care device configuration, with improvements in sleep study outcomes indicating that awake endoscopy is useful during Inspire implant activation.</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with moderate to severe OSA who have undergone Inspire UAS implantation by
             the principal investigator

          -  Must have symptoms of OSA prior to Inspire implantation

          -  AHI between 15 and 65, where central and mixed apnea is 25% or more, and the level of
             collapse is in the soft palate area BMI less than 32

          -  Age 18 or above

        Exclusion Criteria:

          -  Significant central sleep apnea

          -  Presence of other sleep disorders

          -  History of neurologic or neuromuscular disease

          -  Historical or present substance abuse

          -  Bleeding disorders

          -  Autoimmune diseases that increase risk of nasal trauma such as Wegener's, Sarcoidosis,
             etc.

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erica Thaler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

